POISE study scratches itch for Intercept's liver drug
This article was originally published in Scrip
Executive Summary
Additional details from Intercept Pharmaceuticals' Phase III POISE study of obeticholic acid (OCA) in primary biliary cirrhosis (PBC) have provided reassurance that an intolerable itch won't scupper the product's prospects.